IDO1 and colorectal carcinoma: In regard to these inhibitors, it has been proven that IDO1 inhibitors, such as 1-methyltryptophan (1-MT) and epigallocatechin gallate, can act synergistically with immune checkpoint inhibitors to enhance their antitumor efficacy in CRC (Shi et al., 2021).